高脂饮食通过棕榈酰化及AKT激活促进肝脏肿瘤发生
该研究通过代谢物库筛选发现棕榈酸可激活AKT,并利用多种细胞与小鼠模型及人肝组织,阐明高脂饮食经PA-ZDHHC17/24介导的AKT棕榈酰化促进NASH与肝癌发生,奥利司他或穿透肽可减弱该过程。
要点
- 棕榈酸通过促进AKT棕榈酰化激活AKT,为生长因子诱导AKT激活的必要步骤。
- 高脂饮食促进AKT激酶活性,进而促进NASH和肝癌。
- ZDHHC17/24棕榈酰转移酶棕榈酰化AKT发挥致癌作用。
核心结论
- 研究阐明PA-ZDHHC17/24介导的AKT棕榈酰化精细调控新机制,并提示限制PA饮食、限制PA合成或直接靶向AKT棕榈酰化的肿瘤治疗策略。
研究设计与样本
- 研究设计:代谢物库筛选发现棕榈酸可激活AKT;采用体内外棕榈酰化实验检测AKT棕榈酰化;使用多种细胞与小鼠模型,包括AKT1C77S和AKT1C224S敲入细胞、Zdhhc17和Zdhhc24敲除小鼠及Akt1C224S敲入小鼠;进一步探究NASH和HCC患者人肝组织、流体动力学转染小鼠模型、高脂/高胆固醇饮食(HFHCD)诱导NASH/HCC小鼠模型及高脂和甲硫氨酸/胆碱缺乏饮食(HFMCD)诱导NASH小鼠模型。
- 样本:原文未报告具体样本量。
主要发现
- 代谢物库筛选显示棕榈酸通过促进AKT棕榈酰修饰激活AKT,该修饰为生长因子诱导AKT激活的必要步骤。
- 高脂饮食可促进AKT激酶活性,从而促进NASH和肝癌。
- 棕榈酰结合以不依赖PIP3的方式将AKT锚定于细胞膜,部分通过阻止AKT组装成无活性聚合物实现。
- 棕榈酰转移酶ZDHHC17/24被鉴定为棕榈酰化AKT并发挥致癌作用;抗肥胖药奥利司他或特异性穿透肽可分别通过限制PA合成或抑制AKT修饰有效减弱AKT棕榈酰化与激活,从而拮抗肝脏肿瘤发生。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether and how the PI3K-AKT pathway, a central node of metabolic homeostasis, is responsible for high-fat-induced non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) remain a mystery. Characterisation of AKT regulation in this setting will provide new strategies to combat HCC. DESIGN: Metabolite library screening disclosed that palmitic acid (PA) could activate AKT. In vivo and in vitro palmitoylation assay were employed to detect AKT palmitoylation. Diverse cell and mouse models, including generation of AKT1C77S and AKT1C224S knock-in cells, Zdhhc17 and Zdhhc24 knockout mice and Akt1C224S knock-in mice were employed. Human liver tissues from patients with NASH and HCC, hydrodynamic transfection mouse model, high-fat/high-cholesterol diet (HFHCD)-induced NASH/HCC mouse model and high-fat and methionine/choline-deficient diet (HFMCD)-induced NASH mouse model were also further explored for our mechanism studies. RESULTS: By screening a metabolite library, PA has been defined to activate AKT by promoting its palmitoyl modification, an essential step for growth factor-induced AKT activation. Biologically, a high-fat diet could promote AKT kinase activity, thereby promoting NASH and liver cancer. Mechanistically, palmitoyl binding anchors AKT to the cell membrane in a PIP3-independent manner, in part by preventing AKT from assembling into an inactive polymer. The palmitoyltransferases ZDHHC17/24 were characterised to palmitoylate AKT to exert oncogenic effects. Interestingly, the anti-obesity drug orlistat or specific penetrating peptides can effectively attenuate AKT palmitoylation and activation by restricting PA synthesis or repressing AKT modification, respectively, thereby antagonising liver tumorigenesis. CONCLUSIONS: Our findings elucidate a novel fine-tuned regulation of AKT by PA-ZDHHC17/24-mediated palmitoylation, and highlight tumour therapeutic strategies by taking PA-restricted diets, limiting PA synthesis, or directly targeting AKT palmitoylation.
引用
- Bu L, Zhang Z, Chen J, et al. High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT. Gut. 2024. PMID: 38191266. doi:10.1136/gutjnl-2023-330826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。